Achieve Life Sciences (ACHV) completed the US Food and Drug Administration long-term exposure requirement for cytisinicline, a treatment designed to help people quit smoking, with no safety concerns identified.
More than 300 participants completed six months of cumulative cytisinicline treatment in the ORCA-OL clinical trial, the company said Tuesday in a statement.
The company remains on track for the planned New Drug Application submission in Q2.
The company's shares rose 6.2% in recent Tuesday trading.
Price: 3.77, Change: +0.22, Percent Change: +6.20
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。